Timothy Brand, MD
Urology · Tacoma, WANPI 1164539136
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (55.6%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Teleflex LLC at 48.7% of the total. Reporting peaked in 2024 at $2,557 and has fallen 63.7% since, to $928 in 2025.
Across 124 payments — averaging $44.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teleflex LLC$3K
- Janssen Scientific Affairs, LLC$758
- Medtronic$283
- Johnson & Johnson$249
- Coloplast$204
- Sumitomo Pharma America, Inc.$170
- plus $1K from 23 others
Across 2 payments — averaging $2925.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ferring International Pharmascience Center US$5K
- Spectrum Pharmaceuticals Inc.$1K
What the payments were for
- Consulting fees$75814%
- Travel & lodging$1,66930%
- Food & beverage$3,09356%
- Education$401%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teleflex LLC | 17 | $2,705 |
| Janssen Scientific Affairs, LLC | 1 | $758 |
| Medtronic(2 entities) | 6 | $283 |
| Johnson & Johnson | 14 | $249 |
| Coloplast | 23 | $204 |
| Sumitomo Pharma America, Inc. | 9 | $170 |
| AbbVie | 7 | $132 |
| Boston Scientific | 5 | $103 |
| Pfizer | 5 | $101 |
| Urogen Pharma, Inc. | 4 | $89 |
| Endo Pharmaceuticals Inc. | 5 | $88 |
| Intuitive Surgical | 1 | $88 |
| Novartis | 4 | $67 |
| AstraZeneca | 1 | $65 |
| Progenics Pharmaceuticals, Inc. | 3 | $64 |
| Urovant Sciences Inc | 4 | $60 |
| Bayer | 1 | $57 |
| Telix Pharmaceuticals | 2 | $41 |
| KARL Storz Endoscopy-america | 1 | $35 |
| Procept Biorobotics Corporation | 1 | $34 |
| Astellas Pharma US Inc | 2 | $32 |
| Civco Medical Instruments | 1 | $22 |
| Ambu Inc. | 1 | $22 |
| ABC Home Medical Supply, Inc. | 1 | $19 |
| Hollister Incorporated | 1 | $16 |
| Tolmar, Inc. | 1 | $16 |
| Ferring Pharmaceuticals Inc. | 1 | $15 |
| Olympus America Inc. | 1 | $15 |
| Laborie Medical Technologies Corp. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift$2,248
- INTERSTIM$176
- UroLift System$126
- Luja Coude$107
How this compares
$5,559 in reported general payments places this provider in the 75th percentile of 274 urology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 18 | $231,914 |
| XtandiEnzalutamide | 13 | $191,912 |
| MyrbetriqMirabegron | 90 | $85,444 |
| GemtesaVibegron | 32 | $38,296 |
| Tamsulosin Hcl | 248 | $4,123 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 67 | $3,182 |
| Potassium Citrate ErPotassium Citrate | 11 | $1,722 |
| Finasteride | 138 | $1,614 |
| Estradiol | 20 | $1,517 |
| Tolterodine Tartrate ErTolterodine Tartrate | 25 | $1,435 |
| Testosterone Cypionate | 27 | $1,068 |
| Oxybutynin Chloride ErOxybutynin Chloride | 34 | $672 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 21 | $534 |
| Oxybutynin Chloride | 34 | $369 |
| Sildenafil Citrate | 23 | $269 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $32 | $277,356103 claims |
| Johnson & JohnsonErleada | $249 | $231,91418 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $170 | $38,29632 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 274 urology providers in Washington.
Other urology in Tacoma
- Douglas SutherlandTacoma$15K
- Carolyn SalterTacoma$8K
- Francis KimTacoma$7K
- Kevin TsaiTacoma$6K
- James PorterSeattle$471K
- Marah HehemannSeattle$213K
- Raymond LanceSpokane$211K
- Thomas WalshSeattle$186K
- Alvaro LucioniSeattle$148K
- Una LeeSeattle$116K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.